A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome

Intensive Care Medicine, Supplement

Volumn 27, Issue 1, 2001, Pages 1169-1178

  Gallagher, J ^a   Fisher, C ^a   Sherman, B ^a   Munger, M ^a   Meyers, B ^a   Ellison, T ^a   Fischkoff, S ^a   Barchuk, W T ^a   Teoh, L ^a   Velagapudi, R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Afelimomab; Anti TNF antibody; Interleukin 6; MAK 195F; Sepsis; Septic shock

Indexed keywords

AFELIMOMAB; ANTIINFECTIVE AGENT; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HALF LIFE TIME; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INTENSIVE CARE; MALE; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; TREATMENT PLANNING;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIBODIES, MONOCLONAL; CONSUMER PRODUCT SAFETY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALF-LIFE; HUMANS; INTERLEUKIN-6; LOGISTIC MODELS; MALE; MIDDLE AGED; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES;

EID: 0034895949     PISSN: 09351701     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340100973     Document Type: Article

References (38)

1. Sepsis syndrome: A valid clinical entity
2. Severe sepsis and septic shock. Definitions, epidemiology, and clinical manifestations
3. Has the mortality of septic shock changed with time
4. Outcome of intensive care patients in a group of British intensive care units
5. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis
6. Management of septic shock: Present and future
7. A critical evaluation of new agents for the treatment of sepsis
8. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia
9. Correlation of histopathologic and bacteriologic changes with cytokine expression in an experimental murine model of bacteremic Staphylococcus aureus infection
10. Plasma cytokine and endotoxin levels correlate with survival in patients with the sepsis syndrome
11. Serum cytokine levels in human septic shock: Relation to multiple systems organ failure and mortality
12. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever
13. Detection of circulating tumor necrosis factor after endotoxin administration
14. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock
15. Shock and tissue injury induced by human recombinant cachectin
16. Identification of the human 26-kD protein, interferon beta 2 “IFN-beta 2”, as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor
17. Monoclonal antibody to tumor necrosis factor-alpha prevents lethal endotoxin sepsis in adult rhesus monkeys
18. Tumor necrosis factor-neutralization with a specific monoclonal antibody
19. Association of TNF2, a TNF-alpha promoter polymorphism, with septic shock susceptibility and mortality: A multicenter study
20. CDP571, a humanized antibody to human tumor necrosis factor-alpha: Safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group
21. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: A multicenter, randomized, placebo-controlled, dose-ranging study
22. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group
23. Effect of a chimeric antibody to tumor necrosis factor-α on cytokine and physiologic responses in patients with severe sepsis - A randomized, clinical trial
24. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein
25. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial
26. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group
27. Monoclonal antibodies to human tumor necrosis factor alpha: In vitro and in vivo application
28. 2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees
29. Repeated administration of a F “ab′”2 fragment of an anti-tumor necrosis factor alpha monoclonal antibody in patients with severe sepsis: Effects on the cardiovascular system and cytokine levels
30. Clinical safety, tolerability, and pharmacokinetics of murine monoclonal antibody to human tumor necrosis factor-alpha
31. Anti-TNF therapy inhibits fever in cerebral malaria
32. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity
33. Why sepsis trials fail
34. Factors affecting the measurement of cytokines in biological fluids: Implications for their clinical measurement
35. Elimination of interleukin 6 attenuates coagulation activation in experimental endotoxemia in chimpanzees
36. Correlations and interactions in the production of interleukin-6 “IL-6”, IL-1, and tumor necrosis factor “TNF” in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF
37. Interleukin-6 “IL-6” as an anti-inflammatory cytokine: Induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55
38. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multi-center trial